Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?

Int J Cardiol. 2016 Nov 15:223:226-227. doi: 10.1016/j.ijcard.2016.08.182. Epub 2016 Aug 8.

Authors

Luca Vannini¹, Anna Muro¹, Juan Sanchis², Josè T Ortiz-Pérez¹, Eduardo Flores Umanzor¹, Maria Pilar López-Lereu², Lina Badimon³, Manel Sabaté¹, Salvatore Brugaletta⁴

Affiliations

¹ Department of Cardiology, Clinic Cardiovascular Institute, Hospital Clinic, Barcelona, Spain.
² Cardiology Department, Hospital Clínico Universitario, Valencia, School of Medicine, Universitat de València, Valencia, Spain.
³ Cardiovascular Research Center (CSIC-ICCC), IIB-Sant Pau, UAB, Barcelona, Spain.
⁴ Department of Cardiology, Clinic Cardiovascular Institute, Hospital Clinic, Barcelona, Spain. Electronic address: sabrugal@clinic.ub.es.

PMID: 27541661
DOI: 10.1016/j.ijcard.2016.08.182

No abstract available

Keywords: MRI; MVO; Prasugrel; STEMI; Ticagrelor.

MeSH terms

Adenosine / analogs & derivatives*
Adenosine / therapeutic use
Aged
Female
Humans
Magnetic Resonance Imaging
Male
Microvessels
Middle Aged
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / therapeutic use*
Prasugrel Hydrochloride / therapeutic use*
Purinergic P2Y Receptor Antagonists / therapeutic use*
ST Elevation Myocardial Infarction / diagnostic imaging
ST Elevation Myocardial Infarction / physiopathology
ST Elevation Myocardial Infarction / therapy*
Ticagrelor

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Prasugrel Hydrochloride
Ticagrelor
Adenosine